Disadvantages of VKA and requirements for novel anticoagulants
Authors:
- Raji ShameemRSRaji Shameem
- Jack AnsellJAJack Ansell
- 1 June 2013
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 26 (2) , 103-114
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial FibrillationPLOS ONE, 2012
- Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial FibrillationThe American Journal of Cardiology, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- The Oral Thrombin Inhibitor Dabigatran: Strengths and WeaknessesSeminars in Thrombosis and Hemostasis, 2012
- Oral Anticoagulant TherapyChest, 2012
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trialJournal of Thrombosis and Haemostasis, 2011
- Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral AnticoagulationCirculation: Cardiovascular Quality and Outcomes, 2011
- Warfarin and vitamin K intake in the era of pharmacogeneticsBritish Journal of Clinical Pharmacology, 2010
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Risk factors for nonadherence to warfarin: results from the IN‐RANGE studyPharmacoepidemiology and Drug Safety, 2008